Rescue Therapeutics Inc.
Reducing resistance to chemotherapy without added toxicity
This article was originally published in Start Up
The founders of Rescue Therapeutics Inc. believe they have created a compound that can boost the power of widely used generic cancer drugs, including doxorubicin, without exposing a patient to any additional toxicity. Although RTI’s work with the compound was initially geared to testing it against non-Hodgkin's lymphoma, the start-up is taking it forward as a potential second-line treatment for ovarian cancer.
You may also be interested in...
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.
RxMP Therapeutics LLC is working to resolve excessive diffuse bleeding that is often associated with trauma, and also with certain orthopedic and cardiovascular surgeries. The start-up believes it can successfully treat excessive diffuse bleeding with particles produced from the membranes of red blood cells that have been freeze-dried and then, literally, blown to bits.